Table 5. Outcomes of Chronic User Subcohortsa.
| Outcome | Cohort (No.) | Events, No. (%) | Time to event, mean (SD), d | Follow-up, person-years | Events per 100 person-years | HR (95% CI)b |
|---|---|---|---|---|---|---|
| Death | Edaravone (96) | 22 (22.9) | 340.4 (80.8) | 122.3 | 18.0 | 0.77 (0.43-1.18) |
| Riluzole-only (424) | 182 (42.9) | 475.5 (201.4) | 620.9 | 29.3 | ||
| Hospitalization (ALS, dyspnea, or orthopnea) | Edaravone (96) | 18 (18.8) | 254.4 (174.7) | 111.5 | 16.1 | 2.51 (1.18-8.16) |
| Riluzole-only (424) | 35 (8.3) | 199.2 (153.0) | 588.6 | 5.9 | ||
| Tracheostomy | Edaravone (96) | 4 (4.2) | 395.8 (99.4) | 120.8 | 3.3 | 1.22 (0.29-1.63) |
| Riluzole-only (424) | 16 (3.8) | 283.7 (160.3) | 607.8 | 2.6 | ||
| Mechanical ventilation | Edaravone (96) | 9 (9.4) | 320.1 (167.2) | 118.1 | 7.6 | 2.63 (0.90-6.45) |
| Riluzole-only (424) | 17 (4.0) | 279.4 (165.4) | 607.9 | 2.8 | ||
| PEG tube placement | Edaravone (96) | 14 (14.6) | 255.9 (167.0) | 112.8 | 12.4 | 3.04 (1.25-10.66) |
| Riluzole-only (424) | 22 (5.2) | 205.2 (137.7) | 601.5 | 3.7 |
Abbreviations: ALS, amyotrophic lateral sclerosis; HR, hazard ratio; PEG, percutaneous endoscopic gastrostomy.
a
Receiving at least 6 months of treatment.
b
Comparing hazard ratios of the edaravone group to riluzole-only subgroups and Bonferroni-corrected confidence intervals.